These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases. Zhao P; Saltiel AR J Biol Chem; 2020 Aug; 295(34):12279-12289. PubMed ID: 32651233 [TBL] [Abstract][Full Text] [Related]
23. Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway. Wan J; Zhang Y; Yang D; Liang Y; Yang L; Hu S; Liu Z; Fang Q; Tian S; Ding Y Hepatology; 2021 Dec; 74(6):3074-3090. PubMed ID: 34297426 [TBL] [Abstract][Full Text] [Related]
24. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH). Ota T Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745 [TBL] [Abstract][Full Text] [Related]
25. Fructose as a key player in the development of fatty liver disease. Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247 [TBL] [Abstract][Full Text] [Related]
26. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454 [TBL] [Abstract][Full Text] [Related]
27. Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling. Kim MH; Seong JB; Huh JW; Bae YC; Lee HS; Lee DS Redox Biol; 2020 Jan; 28():101315. PubMed ID: 31505325 [TBL] [Abstract][Full Text] [Related]
28. Addressing the liver progenitor cell response and hepatic oxidative stress in experimental non-alcoholic fatty liver disease/non-alcoholic steatohepatitis using amniotic epithelial cells. Goonetilleke M; Kuk N; Correia J; Hodge A; Moore G; Gantier MP; Yeoh G; Sievert W; Lim R Stem Cell Res Ther; 2021 Jul; 12(1):429. PubMed ID: 34321089 [TBL] [Abstract][Full Text] [Related]
29. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice. Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695 [No Abstract] [Full Text] [Related]
30. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice. Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731 [TBL] [Abstract][Full Text] [Related]
31. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease. Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769 [TBL] [Abstract][Full Text] [Related]
32. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis. Yin X; Liu Z; Wang J Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090 [TBL] [Abstract][Full Text] [Related]
33. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237 [TBL] [Abstract][Full Text] [Related]
34. Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition. Huang H; Lee SH; Sousa-Lima I; Kim SS; Hwang WM; Dagon Y; Yang WM; Cho S; Kang MC; Seo JA; Shibata M; Cho H; Belew GD; Bhin J; Desai BN; Ryu MJ; Shong M; Li P; Meng H; Chung BH; Hwang D; Kim MS; Park KS; Macedo MP; White M; Jones J; Kim YB J Clin Invest; 2018 Dec; 128(12):5335-5350. PubMed ID: 30226474 [TBL] [Abstract][Full Text] [Related]
35. Resolvin D3 improves the impairment of insulin signaling in skeletal muscle and nonalcoholic fatty liver disease through AMPK/autophagy-associated attenuation of ER stress. Oh H; Cho W; Abd El-Aty AM; Bayram C; Jeong JH; Jung TW Biochem Pharmacol; 2022 Sep; 203():115203. PubMed ID: 35948170 [TBL] [Abstract][Full Text] [Related]
36. Protective and Detrimental Roles of p38α Mitogen-Activated Protein Kinase in Different Stages of Nonalcoholic Fatty Liver Disease. Hwang S; Wang X; Rodrigues RM; Ma J; He Y; Seo W; Park SH; Kim SJ; Feng D; Gao B Hepatology; 2020 Sep; 72(3):873-891. PubMed ID: 32463484 [TBL] [Abstract][Full Text] [Related]
37. Mitochondria- and NOX4-dependent antioxidant defense mitigates progression to nonalcoholic steatohepatitis in obesity. Greatorex S; Kaur S; Xirouchaki CE; Goh PK; Wiede F; Genders AJ; Tran M; Jia Y; Raajendiran A; Brown WA; McLean CA; Sadoshima J; Watt MJ; Tiganis T J Clin Invest; 2023 Dec; 134(3):. PubMed ID: 38060313 [TBL] [Abstract][Full Text] [Related]